Agent Capital

A study published in Nature Biotechnology by the Perelman School of Medicine at the University of Pennsylvania highlights the potential of genetically engineered macrophages in immunotherapy for solid tumors.

Freenome is initiating its PREEMPT CRC clinical trial, which will enroll 14,000 individuals to validate its multiomics blood test for CRC screening and FDA approval.

In a historic year for Kauffman Fellows, the 2-year fellowship program welcomes 64 exceptionally diverse and highly talented leaders into Class 23.

By John George of the Philadelphia Business Journal Another Philadelphia biopharmaceutical company spun out the University of Pennsylvania and targeting cancer has attracted a multimillion-dollar investment. News article here.

Aptinyx Inc., a clinical-stage biopharmaceutical company, announces pricing of its initial public offering (IPO).

Carisma Therapeutics raises $53 million in Series A financing to further expand its technology and rapidly drive its programs toward clinical development.

Catch up on Agent Capital's latest news and portfolio company announcements.

Orchard Therapeutics raises $110 million (£85 million) in Series B financing. Proceeds of the Series B round will be used to rapidly progress Orchard’s pipeline.

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that improve patients' lives.

Agent Capital says its strategy guides biotech companies to milestones and exits.

Agent Capital is a healthcare venture capital firm addressing unmet patient needs.

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics & treatments that address unmet patient needs.